SUBSCRIBE
SUBSCRIBE

Panbela Therapeutics Inc.

IN THE PRESS
BioMidwest
Panbela Announces Poster Presentation at American Association for Cancer Research:Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
April 18, 2024
 · 
8 min read
BioMidwest
Panbela Announces Transfer to OTCQB Market
April 16, 2024
 · 
7 min read
Business
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
March 26, 2024
 · 
14 min read
BioMidwest
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
March 12, 2024
 · 
6 min read
Policy
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 15, 2024
 · 
6 min read
Deals
Panbela Announces Closing of Approximately $9.0 Million Public Offering
February 1, 2024
 · 
5 min read
BioMidwest
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
January 30, 2024
 · 
6 min read
BioMidwest
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
January 29, 2024
 · 
7 min read
BioMidwest
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
January 25, 2024
 · 
6 min read
Drug Development
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
January 18, 2024
 · 
6 min read
Load More
JOBS